Skip to main content

Variation ID'd in Risk for Second Primary Cancer After Breast Cancer

Medically reviewed by Carmen Pope, BPharm. Last updated on April 30, 2024.

By Elana Gotkine HealthDay Reporter

TUESDAY, April 30, 2024 -- The risk for second primary cancer (SPC) after breast cancer (BC) varies with gender, age, and socioeconomic status, according to a study published online April 24 in The Lancet Regional Health: Europe.

Isaac Allen, from the National Health Service England in London, and colleagues estimated standardized incidence ratios (SIRs) for combined and site-specific SPCs using incidences for England, overall, and by age at BC and socioeconomic status in a cohort including 581,403 female and 3,562 male BC survivors diagnosed between 1995 and 2019.

The researchers found that both women and men had an increased risk for contralateral breast (SIRs, 2.02 for women and 55.4 for men) and nonbreast SPC (SIRs, 1.10 for women and 1.10 for men). Women who were younger at BC diagnosis had higher nonbreast SPC risks (SIRs, 1.34 at younger than 50 years and 1.07 at 50 years or older), as did those who were more socioeconomically deprived (SIR, 1.34 for most deprived quintile).

"We assessed the variation in SPC risks by a wide range of sociodemographic factors, first tumor characteristics, and BC treatments and found that SPC risks are elevated among BC survivors living in more socioeconomically deprived regions at diagnosis," the authors write.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

Inavolisib + Palbociclib-Fulvestrant Improves Survival in Advanced Breast Cancer

THURSDAY, Oct. 31, 2024 -- Inavolisib plus palbociclib-fulvestrant yields significantly longer progression-free survival than placebo plus palbociclib-fulvestrant in patients with...

Multigene Signature Can Help Tailor Chemo for Operable Triple-Negative Breast Cancer

WEDNESDAY, Oct. 30, 2024 -- For patients with operative triple-negative breast cancer, a multigene signature can help tailor adjuvant chemotherapy, according to a study published...

American College of Surgeons, Oct. 19-22

The annual meeting of the American College of Surgeons was held this year from Oct. 19 to 22 in San Francisco and attracted participants from around the world, including...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.